<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: A most important characteristic feature for poor prognosis in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is the presence of lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Determination of carcinoembryonic antigen (CEA) <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels in lymph nodes has proven powerful for quantification of disseminated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we investigate the utility of human tissue kallikrein-related peptidase 6 (KLK6) <z:chebi fb="2" ids="33699">mRNA</z:chebi> as a progression biomarker to complement CEA <z:chebi fb="2" ids="33699">mRNA</z:chebi>, for improved selection of patients in need of adjuvant therapy and intensified follow-up after surgery </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Lymph nodes of pTNM stage I-IV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>- (166 patients/503 lymph nodes) and control (23/108) patients were collected at surgery and analysed by quantitative RT-PCR </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Lymph node KLK6 positivity was an indicator of poor outcome (hazard ratio 3.7) </plain></SENT>
<SENT sid="5" pm="."><plain>Risk of recurrence and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> increased with KLK6 lymph node levels </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with KLK6 lymph node levels above the 90th percentile had a hazard ratio of 6.5 and 76 months shorter average survival time compared to patients with KLK6 negative nodes </plain></SENT>
<SENT sid="7" pm="."><plain>The KLK6 positivity in lymph nodes with few <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells, that is, low CEA <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels, also indicated poor prognosis (hazard ratio 2.8) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients, lymph node KLK6 positivity indicated presence of aggressive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells associated with poor prognosis and high risk of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> recurrence </plain></SENT>
</text></document>